Antibiotics are crown to the modern medicine, and they are the weapon against numerous infectious diseases. The exposure of bacteria to ‘non-lethal levels’ of antibiotics is causing antibiotic resistance (ABR) in them. Multidrug resistance (MDR) is the most common type of resistance. The MDR refers to bacteria showing resistance to at least three different classes of antimicrobials. There is a worrying increase in the ABR since 1990s, on the other hand, the new antibiotic research is decreasing.
In this article, a careful examination was made on MDR bacteria and multiple mechanisms that made them resistant. Following which the focus is on the new components that are in pipeline, active against MDR. The leading antibacterial drugs in clinical development (Phase III) from 2017 to 2020 are mentioned first, followed by new pharmacologically interesting agents that were approved during the same period. It concludes with the benefits from the usage of these pharmacological compounds, and importance of poorly developed techniques such as Nanoparticles delivery systems for antibiotics.
To know more about the clinical development of the compounds, please visit the website of PMC (Link).